Smoking intensity and lipoprotein abnormalities in active smokers

Journal of Clinical Lipidology

Volumn 3, Issue 6, 2009, Pages 372-378

  Gossett, Linda K ^a   Johnson, Heather M ^a   Piper, Megan E ^a   Fiore, Michael C ^a   Baker, Timothy B ^a   Stein, James H ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

High density lipoprotein cholesterol; Lipoproteins; Low density lipoprotein cholesterol; Risk factors; Smoking; Triglycerides

Indexed keywords

ANTILIPEMIC AGENT; CARBON MONOXIDE; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGE; AGED; ALCOHOL CONSUMPTION; ARTICLE; CIGARETTE SMOKING; COHORT ANALYSIS; DYSLIPOPROTEINEMIA; FEMALE; GENDER; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARTICLE SIZE; PHYSICAL ACTIVITY; PRIORITY JOURNAL; RACE; SCORING SYSTEM; SMOKING CESSATION; TOBACCO DEPENDENCE; WAIST CIRCUMFERENCE;

EID: 71549125556     PISSN: 19332874     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacl.2009.10.008     Document Type: Article

References (31)

1. Yusuf S., Hawken S., Ounpuu S., et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364 (2004) 937-952
2. Craig W.Y., Palomaki G.E., and Haddow J.E. Cigarette smoking and serum lipid and lipoprotein concentrations: an analysis of published data. BMJ 298 (1989) 784-788
3. Ambrose J.A., and Barua R.S. The pathophysiology of cigarette smoking and cardiovascular disease: an update. J Am Coll Cardiol 43 (2004) 1731-1737
4. Teo K.K., Ounpuu S., Hawken S., et al. Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control study. Lancet 368 (2006) 647-658
5. Campbell S.C., Moffatt R.J., and Stamford B.A. Smoking and smoking cessation-the relationship between cardiovascular disease and lipoprotein metabolism: a review. Atherosclerosis 201 (2008) 225-235
6. National Cholesterol Education Program (NCEP) Expert Panel (ATP III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106 (2002) 3143-3421
7. Sacks F.M. The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: expert group recommendations. Am J Cardiol 90 (2002) 139-143
8. Rosenson R.S. Low HDL-C: a secondary target of dyslipidemia therapy. Am J Med 118 (2005) 1067-1077
9. Singh I.M., Shishehbor M.H., and Ansell B.J. High-density lipoprotein as a therapeutic target: a systematic review. JAMA 298 (2007) 786-798
10. Mosca L., Banka C.L., Benjamin E.J., et al. Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. Circulation 115 (2007) 1481-1501
11. Smith Jr. S.C., Allen J., Blair S.N., et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 113 (2006) 2363-2372
12. Brunzell J.D., Davidson M., Furberg C.D., et al. Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol 51 (2008) 1512-1524
13. Stein J.H., and McBride P.E. Should advanced lipoprotein testing be used in clinical practice?. Nat Clin Pract Cardiovasc Med 3 (2006) 640-641
14. Principal Investigator: Timothy B. Baker, PhD. University of Wisconsin, Madison. Smoking Cessation Medications: Efficacy, Mechanisms and Algorithms. Study Identifier NCT00332644. Available at: http://clinicaltrials.gov/ct2/show/NCT00332644. Website last accessed on May 19, 2009.
15. Craig C.L., Marshall A.L., Sjostrom M., et al. International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc 35 (2003) 1381-1395
16. Heatherton T.F., Kozlowski L.T., Frecker R.C., and Fagerstrom K.O. The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br J Addict 86 (1991) 1119-1127
17. Jeyarajah E.J., Cromwell W.C., and Otvos J.D. Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. Clin Lab Med 26 (2006) 847-870
18. Onat A., Uyarel H., Hergenc G., Karabulut A., Albayrak S., and Can G. Determinants and definition of abdominal obesity as related to risk of diabetes, metabolic syndrome and coronary disease in Turkish men: a prospective cohort study. Atherosclerosis 191 (2007) 182-190
19. Onat A., Ozhan H., Esen A.M., et al. Prospective epidemiologic evidence of a "protective" effect of smoking on metabolic syndrome and diabetes among Turkish women-without associated overall health benefit. Atherosclerosis 193 (2007) 380-388
20. Rimm E.B., Manson J.E., Stampfer M.J., et al. Cigarette smoking and the risk of diabetes in women. Am J Public Health 83 (1993) 211-214
21. McNeill A. Harm reduction. BMJ 328 (2004) 885-887
22. Hughes J.R. Harm-reduction approaches to smoking. The need for data. Am J Prev Med 15 (1998) 78-79
23. Batra A., Klingler K., Landfeldt B., et al. Smoking reduction treatment with 4-mg nicotine gum: a double-blind, randomized, placebo-controlled study. Clin Pharmacol Ther 78 (2005) 689-696
24. Rennard S.I., Glover E.D., Leischow S., et al. Efficacy of the nicotine inhaler in smoking reduction: A double-blind, randomized trial. Nicotine Tob Res 8 (2006) 555-564
25. Stead L.F., and Lancaster T. Interventions to reduce harm from continued tobacco use. Cochrane Database Syst Rev (2007) CD005231
26. Stratton K., Shetty P., Wallace R., and Bondurant S. Clearing the smoke: the science base for tobacco harm reduction-executive summary. Tob Control 10 (2001) 189-195
27. Wilson P.W., Garrison R.J., Abbott R.D., and Castelli W.P. Factors associated with lipoprotein cholesterol levels. The Framingham study. Arteriosclerosis 3 (1983) 273-281
28. Criqui M.H., Wallace R.B., Heiss G., et al. Cigarette smoking and plasma high-density lipoprotein cholesterol. The Lipid Research Clinics Program Prevalence Study. Circulation 62 (1980) IV70-IV76
29. Ellison R.C., Zhang Y., Qureshi M.M., et al. Lifestyle determinants of high-density lipoprotein cholesterol: the National Heart, Lung, and Blood Institute Family Heart Study. Am Heart J 147 (2004) 529-535
30. LaRowe T.L., Piper M.E., Schlam T.R., Fiore M.C., and Baker T.B. Obesity and smoking: comparing cessation treatment seekers with the general smoking population. Obesity (Silver Spring) 17 (2009) 1301-1305
31. Haffner S.M., D'Agostino Jr. R., Goff D., et al. LDL size in African Americans, Hispanics, and non-Hispanic whites: the insulin resistance atherosclerosis study. Arterioscler Thromb Vasc Biol 19 (1999) 2234-2240